|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Mathers C, Parkin DM, Piñeros M, Znaor A and Bray F: Estimating the
global cancer incidence and mortality in 2018: GLOBOCAN sources and
methods. Int J Cancer. 144:1941–1953. 2019. View Article : Google Scholar
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 coun-tries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Burdett S, Stewart L and Pignon JP:
Chemotherapy in non-small cell lung cancer: An update of an
individual patient data-based meta-analysis. J Thorac Cardiovasc
Surg. 129:1205–1206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
NSCLC Meta-Analyses Collaborative Group:
Chemotherapy in addition to supportive care improves survival in
advanced non-small-cell lung cancer: A systematic review and
meta-analysis of individual patient data from 16 randomized
controlled trials. J Clin Oncol. 26:4617–4625. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Baselga J and Averbuch SD: ZD1839
('Iressa') as an anticancer agent. Drugs. 60(Suppl 1): S33–S42.
2000. View Article : Google Scholar
|
|
6
|
Singh M and Jadhav HR: Targeting non-small
cell lung cancer with small-molecule EGFR tyrosine kinase
inhibitors. Drug Discov Today. 23:745–753. 2018. View Article : Google Scholar
|
|
7
|
Wu SG and Shih JY: Management of acquired
resistance to EGFR TKI-targeted therapy in advanced non-small cell
lung cancer. Mol Cancer. 17:382018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jänne PA, Yang JC, Kim DW, Planchard D,
Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, et al: AZD9291
in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J
Med. 372:1689–1699. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang JC, Hirsh V, Schuler M, Yamamoto N,
O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey
D, et al: Symptom control and quality of life in LUX-Lung 3: A
phase III study of afatinib or cisplatin/pemetrexed in patients
with advanced lung adenocarcinoma with EGFR mutations. J Clin
Oncol. 31:3342–3350. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Takeda H, Takigawa N, Ohashi K, Minami D,
Kataoka I, Ichihara E, Ochi N, Tanimoto M and Kiura K: Vandetanib
is effective in EGFR-mutant lung cancer cells with PTEN deficiency.
Exp Cell Res. 319:417–423. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Costa DB, Shaw AT, Ou SH, Solomon BJ,
Riely GJ, Ahn MJ, Zhou C, Shreeve SM, Selaru P, Polli A, et al:
Clinical experience with crizotinib in patients with advanced
ALK-rearranged non-small-cell lung cancer and brain metastases. J
Clin Oncol. 33:1881–1888. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Z, Luo F, Zhang Y, Ma Y, Hong S,
Yang Y, Fang W, Huang Y, Zhang L and Zhao H: The ACTIVE study
protocol: Apatinib or placebo plus gefitinib as first-line
treatment for patients with EGFR-mutant advanced non-small cell
lung cancer (CTONG1706). Cancer Commun (Lond). 39:692019.
View Article : Google Scholar
|
|
13
|
Kim D, Bach DH, Fan YH, Luu TT, Hong JY,
Park HJ and Lee SK: AXL degradation in combination with EGFR-TKI
can delay and overcome acquired resistance in human non-small cell
lung cancer cells. Cell Death Dis. 10:3612019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang W, Wang H, Lu P, Yu Z, Xu C, Zhuang W
and Song Z: Crizotinib with or without an EGFR-TKI in treating
EGFR-mutant NSCLC patients with acquired MET amplification after
failure of EGFR-TKI therapy: A multicenter retrospective study. J
Transl Med. 17:522019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou H, Zeng C, Wang LY, Xie H, Zhou J,
Diao P, Yao WX, Zhao X and Wei Y: Chemotherapy with or without
gefitinib in patients with advanced non-small-cell lung cancer: A
meta-anal-ysis of 6,844 patients. Chin Med J (Engl). 126:3348–3355.
2013.
|
|
16
|
Fang H, Lin RY, Sun MX, Wang Q, Zhao YL,
Yu JL, Tian Y and Wang XY: Efficacy and survival-associated factors
with gefitinib combined with cisplatin and gemcitabine for advanced
non-small cell lung cancer. Asian Pac J Cancer Prev.
15:10967–10970. 2014. View Article : Google Scholar
|
|
17
|
Lee S, Joo J, Kwak M, Sohn K and Chon S:
Role of chemo-therapy with epidermal growth factor
receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small
cell transformation after EGFR-TKI failure: A case report. Onco
Targets Ther. 11:3943–3947. 2018. View Article : Google Scholar :
|
|
18
|
Ding T, Zhou F, Chen X, Zhang S, Liu Y,
Sun H, Ren S, Li X, Zhao C, Wang H and Zhou C: Continuation of
gefitinib plus chemo-therapy prolongs progression-free survival in
advanced non-small cell lung cancer patients who get acquired
resistance to gefitinib without T790M mutations. J Thorac Dis.
9:2923–2934. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Anderson NG, Ahmad T, Chan K, Dobson R and
Bundred NJ: ZD1839 (Iressa), a novel epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the
growth of EGFR-positive cancer cell lines with or without erbB2
overexpression. Int J Cancer. 94:774–782. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Anido J, Matar P, Albanell J, Guzmán M,
Rojo F, Arribas J, Averbuch S and Baselga J: ZD1839, a specific
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor,
induces the formation of inactive EGFR/HER2 and EGFR/HER3
heterodimers and prevents heregulin signaling in
HER2-overexpressing breast cancer cells. Clin Cancer Res.
9:1274–1283. 2003.PubMed/NCBI
|
|
21
|
Roberts JJ and Friedlos F: Quantitative
estimation of cisplatin-induced DNA interstrand cross-links and
their repair in mammalian cells: Relationship to toxicity.
Pharmacol Ther. 34:215–246. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dijt FJ, Fichtinger-Schepman AM, Berends F
and Reedijk J: Formation and repair of cisplatin-induced adducts to
DNA in cultured normal and repair-deficient human fibroblasts.
Cancer Res. 48:6058–6062. 1988.PubMed/NCBI
|
|
23
|
Pera MF Jr, Rawlings CJ and Roberts JJ:
The role of DNA repair in the recovery of human cells from
cisplatin toxicity. Chem Biol Interact. 37:245–261. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chu G and Berg P: DNA cross-linked by
cisplatin: A new probe for the DNA repair defect in xeroderma
pigmentosum. Mol Biol Med. 4:277–290. 1987.PubMed/NCBI
|
|
25
|
Shao CJ, Fu J, Shi HL, Mu YG and Chen ZP:
Activities of DNA-PK and Ku86, but not Ku70, may predict
sensitivity to cisplatin in human gliomas. J Neurooncol. 89:27–35.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ryu JS, Memon A and Lee SK: ERCC1 and
personalized medicine in lung cancer. Ann Transl Med.
2:322014.PubMed/NCBI
|
|
27
|
Wang LR, He LJ, Wang Y, Li YY, Lou Y,
Zhang GB, Li Y and Chen J: Correlation between BRCA1 and TopBP1
protein expression and clinical outcome of non-small cell lung
cancer treated with platinum-based chemotherapy. Cancer Chemother
Pharmacol. 76:163–170. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang SC and Hung MC: Nuclear translocation
of the epidermal growth factor receptor family membrane tyrosine
kinase receptors. Clin Cancer Res. 15:6484–6489. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rodemann HP, Dittmann K and Toulany M:
Radiation-induced EGFR-signaling and control of DNA-damage repair.
Int J Radiat Biol. 83:781–791. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang SC, Nakajima Y, Yu YL, Xia W, Chen
CT, Yang CC, McIntush EW, Li LY, Hawke DH, Kobayashi R and Hung MC:
Tyrosine phosphorylation controls PCNA function through protein
stability. Nat Cell Biol. 8:1359–1368. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Das AK, Chen BP, Story MD, Sato M, Minna
JD, Chen DJ and Nirodi CS: Somatic mutations in the tyrosine kinase
domain of epidermal growth factor receptor (EGFR) abrogate
EGFR-mediated radioprotection in non-small cell lung carcinoma.
Cancer Res. 67:5267–5274. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liccardi G, Hartley JA and Hochhauser D:
EGFR nuclear translocation modulates DNA repair following cisplatin
and ionizing radiation treatment. Cancer Res. 71:1103–1114. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee GY, Kenny PA, Lee EH and Bissell MJ:
Three-dimensional culture models of normal and malignant breast
epithelial cells. Nat Methods. 4:359–365. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Westover D, Zugazagoitia J, Cho BC, Lovly
CM and Paz-Ares L: Mechanisms of acquired resistance to first- and
second-generation EGFR tyrosine kinase inhibitors. Ann Oncol.
29(Suppl 1): i10–i19. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Q, Kanterewicz B, Shoemaker S, Hu Q,
Liu S, Atwood K and Hershberger P: Differential response to
1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung
cancer cells with distinct oncogene mutations. J Steroid Biochem
Mol Biol. 136:264–270. 2013. View Article : Google Scholar
|
|
37
|
Takezawa K, Okamoto I, Yonesaka K,
Hatashita E, Yamada Y, Fukuoka M and Nakagawa K: Sorafenib inhibits
non-small cell lung cancer cell growth by targeting B-RAF in KRAS
wild-type cells and C-RAF in KRAS mutant cells. Cancer Res.
69:6515–6521. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li T, Ling YH, Goldman ID and Perez-Soler
R: Schedule-dependent cytotoxic synergism of pemetrexed and
erlotinib in human non-small cell lung cancer cells. Clin Cancer
Res. 13:3413–3422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang W, Peyton M, Xie Y, Soh J, Minna JD,
Gazdar AF and Frenkel EP: Histone deacetylase inhibitor romidepsin
enhances anti-tumor effect of erlotinib in non-small cell lung
cancer (NSCLC) cell lines. J Thorac Oncol. 4:161–166. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Van Schaeybroeck S, Kyula J, Kelly DM,
Karaiskou-McCaul A, Stokesberry SA, Van Cutsem E, Longley DB and
Johnston PG: Chemotherapy-induced epidermal growth factor receptor
activation determines response to combined gefitinib/chemotherapy
treatment in non-small cell lung cancer cells. Mol Cancer Ther.
5:1154–1165. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kim GW, Song JS, Choi CM, Rho JK, Kim SY,
Jang SJ, Park YS, Chun SM, Kim WS, Lee JS, et al: Multiple
resistant factors in lung cancer with primary resistance to EGFR-TK
inhibitors confer poor survival. Lung Cancer. 88:139–146. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Karachaliou N, Rosell R, Molina MA and
Viteri S: Predicting resistance by selection of signaling pathways.
Transl Lung Cancer Res. 3:107–115. 2014.
|
|
43
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Denis MG, Vallée A and Théoleyre S: EGFR
T790M resistance mutation in non small-cell lung carcinoma. Clin
Chim Acta. 444:81–85. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sordella R, Bell DW, Haber DA and
Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer
activate anti-apoptotic pathways. Science. 305:1163–1167. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Vitale MG, Riccardi F, Mocerino C, Barbato
C, Monaco R, Galloro P, Gagliardi N and Cartenì G:
Erlotinib-induced complete response in a patient with epidermal
growth factor receptor wild-type lung adenocarcinoma after
chemotherapy failure: A case report. J Med Case Rep. 8:1022014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Tsai CM, Chen JT, Stewart DJ, Chiu CH, Lai
CL, Hsiao SY, Chen YM and Chang KT: Antagonism between gefitinib
and cisplatin in non-small cell lung cancer cells: Why randomized
trials failed? J Thorac Oncol. 6:559–568. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Laurila N and Koivunen JP: EGFR inhibitor
and chemotherapy combinations for acquired TKI resistance in
EGFR-mutant NSCLC models. Med Oncol. 32:2052015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhang Y, Yang H, Yang X, Deng Q, Zhao M,
Xu X and He J: Erlotinib with pemetrexed/cisplatin for patients
with EGFR wild-type lung adenocarcinoma with brain metastases. Mol
Clin Oncol. 2:449–453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pao W, Wang TY, Riely GJ, Miller VA, Pan
Q, Ladanyi M, Zakowski MF, Heelan RT, Kris MG and Varmus HE: KRAS
mutations and primary resistance of lung adenocarcinomas to
gefitinib or erlotinib. PLoS Med. 2:e172005. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Eberhard DA, Johnson BE, Amler LC, Goddard
AD, Heldens SL, Herbst RS, Ince WL, Jänne PA, Januario T, Johnson
DH, et al: Mutations in the epidermal growth factor receptor and in
KRAS are predictive and prognostic indicators in patients with
non-small-cell lung cancer treated with chemotherapy alone and in
combination with erlotinib. J Clin Oncol. 23:5900–5909. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rosetti M, Zoli W, Tesei A, Ulivi P,
Fabbri F, Vannini I, Brigliadori G, Granato AM, Amadori D and
Silvestrini R: Iressa strengthens the cytotoxic effect of docetaxel
in NSCLC models that harbor specific molecular characteristics. J
Cell Physiol. 212:710–716. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang
JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, et al: Gefitinib plus
chemotherapy versus chemotherapy in epidermal growth factor
receptor mutation-positive non-small-cell lung cancer resistant to
first-line gefitinib (IMPRESS): Overall survival and biomarker
analyses. J Clin Oncol. 35:4027–4034. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Melisi D, Troiani T, Damiano V, Tortora G
and Ciardiello F: Therapeutic integration of signal transduction
targeting agents and conventional anti-cancer treatments. Endocr
Relat Cancer. 11:51–68. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Fujiwara K, Kiura K, Gemba K, Ogata Y,
Hotta K, Kishino D, Tabata M, Ueoka H and Tanimoto M: Gefitinib
('Iressa', ZD1839) may restore chemosensitivity in NSCLC patients?
Anticancer Res. 25:547–549. 2005.PubMed/NCBI
|
|
56
|
Dai Q, Ling YH, Lia M, Zou YY, Kroog G,
Iwata KK and Perez-Soler R: Enhanced sensitivity to the
HER1/epidermal growth factor receptor tyrosine kinase inhibitor
erlotinib hydro-chloride in chemotherapy-resistant tumor cell
lines. Clin Cancer Res. 11:1572–1578. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Hilger RA, Scheulen ME and Strumberg D:
The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie.
25:511–518. 2002.
|
|
58
|
Cheng GZ, Park S, Shu S, He L, Kong W,
Zhang W, Yuan Z, Wang LH and Cheng JQ: Advances of AKT pathway in
human oncogenesis and as a target for anti-cancer drug discovery.
Curr Cancer Drug Targets. 8:2–6. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Sharrard RM and Maitland NJ: Regulation of
protein kinase B activity by PTEN and SHIP2 in human
prostate-derived cell lines. Cell Signal. 19:129–138. 2007.
View Article : Google Scholar
|
|
60
|
Kokubo Y, Gemma A, Noro R, Seike M,
Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M
and Kudoh S: Reduction of PTEN protein and loss of epidermal growth
factor receptor gene mutation in lung cancer with natural
resistance to gefitinib (IRESSA). Br J Cancer. 92:1711–1719. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Albitar L, Carter MB, Davies S and Leslie
KK: Consequences of the loss of p53, RB1, and PTEN: Relationship to
gefitinib resistance in endometrial cancer. Gynecol Oncol.
106:94–104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yamamoto C, Basaki Y, Kawahara A,
Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K,
Kuwano M and Ono M: Loss of PTEN expression by blocking nuclear
translocation of EGR1 in gefitinib-resistant lung cancer cells
harboring epidermal growth factor receptor-activating mutations.
Cancer Res. 70:8715–8725. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Friedmann BJ, Caplin M, Savic B, Shah T,
Lord CJ, Ashworth A, Hartley JA and Hochhauser D: Interaction of
the epidermal growth factor receptor and the DNA-dependent protein
kinase pathway following gefitinib treatment. Mol Cancer Ther.
5:209–218. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Friedmann B, Caplin M, Hartley JA and
Hochhauser D: Modulation of DNA repair in vitro after treatment
with chemotherapeutic agents by the epidermal growth factor
receptor inhibitor gefitinib (ZD1839). Clin Cancer Res.
10:6476–6486. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Dittmann K, Mayer C, Fehrenbacher B,
Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R and Rodemann HP:
Radiation-induced epidermal growth factor receptor nuclear import
is linked to activation of DNA-dependent protein kinase. J Biol
Chem. 280:31182–31189. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Dittmann K, Mayer C and Rodemann HP:
Inhibition of radiation-induced EGFR nuclear import by C225
(Cetuximab) suppresses DNA-PK activity. Radiother Oncol.
76:157–161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Dittmann K, Mayer C, Czemmel S, Huber SM
and Rodemann HP: New roles for nuclear EGFR in regulating the
stability and translation of mRNAs associated with VEGF signaling.
PLoS One. 12:e01890872017. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Sok JC, Coppelli FM, Thomas SM, Lango MN,
Xi S, Hunt JL, Freilino ML, Graner MW, Wikstrand CJ, Bigner DD, et
al: Mutant epidermal growth factor receptor (EGFRvIII) contributes
to head and neck cancer growth and resistance to EGFR targeting.
Clin Cancer Res. 12:5064–5073. 2006. View Article : Google Scholar : PubMed/NCBI
|
